during prolonged administration in patients with
|
|
- Meagan Ramsey
- 5 years ago
- Views:
Transcription
1 Journal of Neurology, Neurosurgery, and Psychiatry 1982;45: Controlled study of metoprolol and propranolol during prolonged administration in patients with essential tremor S CALZETTI,* LJ FINDLEY,* E PERUCCA,J A RICHENSt From the Medical Research Council, Hearing and Balance Unit, The National Hospital, Queen Square, London, * Istituto di Farmacologia Medica, Universita di Pavia, Pavia, Italyt and the Department of Pharmacology and Therapeutics, Welsh National School ofmedicine, Cardiff, Walest SUMMARY The efficacy of propranolol and metoprolol in the treatment of essential tremor was compared in a double blind crossover placebo-controlled study in 16 patients. Each treatment was given for a period of 4 weeks at two different dosage regimens (150 and 300 mg daily for metoprolol, 120 and 240 mg daily for propranolol). Each dosage regimen lasted for 2 weeks. Tremor assessment was carried out by accelerometry, clinical evaluation, patient's self-rating and a battery of performance tests. At the lower dosage, propranolol was found to be superior to placebo on the basis of performance tests and patient's self-assessment. At the higher dosage, propranolol was superior to placebo on all methods of assessment. By contrast, the tremorolytic effect of metoprolol was not significantly different from that of placebo, irrespective of the dosage or of the method of assessment used. Propranolol (120 mg daily) was better than metoprolol (150 mg daily) on the basis of clinical evaluation and patient's self-assessment. Propranolol (240 mg daily) was superior to metoprolol (300 mg daily) on the basis of patient's self-assessment. Both drugs antagonised standing tachycardia to a similar extent. These results indicate that the effectiveness of metoprolol, previously demonstrated in a single-dose study in the same patients, is not fully maintained during prolonged administration. In the absence of specific contraindications, propranolol represents a better choice in the treatment of patients with essential tremor. The role of fli-selective adrenoceptor antagonists in the symptomatic relief of essential tremor has not been yet clearly established. Following initial reports claiming that metoprolol is effective,`-5 the controlled studies conducted so far with either metoprolol or atenolol have led to conflicting results.68 In some of these studies, however, fi -selective drugs have been compared with non selective 13-adrenoceptor antagonists such as propranolol and sotalol at dosages not having equipotent fl-blocking activity, thus making it difficult to obtain a quantitative assessment of their comparative tremorolytic potencies. This issue has important therapeutic implications because fi,- selective drugs may represent an alternative to Address for reprint requests: Dr Stefano Calzetti, Istituto di Clinica Neurologica, Via del Quartiere Parmna, Italy. Received 27 March Accepted 19 May propranolol in patients with essential tremor and obstructive disease of the upper airways. In a previous study9 we found that a single oral dose of metoprolol (150 mg) reduced the amplitude of essential tremor to virtually the same extent as a fli-equipotent dose of propranolol (120 mg). This encouraging observation led us to compare the efficacy of these two drugs following prolonged administration in the same population of patients. Methods Patients Sixteen patients affected by moderate to severe essential tremor (eight male and eight female) aged between 20 and 72 years (mean age 43 years) and attending the out patient clinics at the National Hospital for Nervous Diseases, Queen Square, gave their informed consent to participate in the study. The diagnosis was established on the basis of the clinical history and detailed general and neurological examination accompanied by ancillary laboratory investigations, where 893
2 894 necessary. All patients had been symptomatic for at least 1 year (range 1 to 43 years) prior to the study. In nine patients there was a family history of tremor affecting hands or head or both. Fifteen patients had previously taken part in a single oral dose study with the same drugs.9 No patient was receiving any drug therapy for tremor at the time of the study but nine of them had been previously treated with propranolol (range mg daily). Patients with a history of excessive alcohol intake, congestive heart failure, A-V block, diabetes mellitus and asthma were excluded. Protocol The study was double-blind and consisted of three treatments (metoprolol, propranolol and placebo) arranged according to a crossover design. Each treatment lasted for four weeks. The active treatments consisted of two consecutive periods (each lasting for two weeks) during which two dosage regimens were used: 120 and 240 mg (as 40 or 80 mg tablets) daily for propranolol and 150 and 300 mg (as 50 or 100 mg tablets) daily for metoprolol. These doses are considered, on the basis of literature data, to produce a comparable degree of cardiac fl-blockade. ' The order of treatment was randomised, but within each active treatment period the lower dosage always preceded the higher dosage regimen. Drug (or placebo) were given in three equally divided daily doses. All tablets looked alike and the same number of tablets was taken in any one day of the study. Assessment of hand tremor was performed at the end of each dosage period (that is every two weeks) as near as possible at the same time of day for each patient. Patients were instructed to take the previous dose about 2 hours before testing. Tremor was measured by means of piezoresistive linear accelerometers (ENDEVCO ) attached to the dorsal surface of the outstretched hands, the forearms being supported up to the wrists.9 On each recording session three separate tremor recordings of about 3 min duration were obtained at 5 min intervals. The signal was amplified, recorded on paper and stored on magnetic tape for off-line spectrum analysis. The following parameters were determined: dominant peak frequency (Hz), acceleration (g) and amplitude of hand displacement (mm). Only the data of the more severely affected hand were used for the computation of results. Details of the recording and analysis procedures have been described elsewhere.9 At the completion of the accelerometric recordings, clinical evaluation of the postural tremor of the more involved hand (held in the same position used for accelerometric recording) was carried out. Additional evaluations included the patient's self-assessment of tremor severity during daily activities and tests of performance (hand-writing, drawing geometrical figures and tracing an Archimede's spiral). A score from 0 to 5 (maximum of tremor severity) was used for the rating of each parameter. For the tests of performance, the mean score derived from the rating of three independent investigators was used for the statistical analysis. Measurements of pulse rate were obtained after a 10 min rest in the supine position and repeated after 1, 2 and 3 min of standing (the mean of these three values was used for the analysis). The inhibition of standing tachycardia was used as Calzetti, Findley, Perucca, Richens an approximate indication of cardiac/i-blockade. " Venous blood samples for the determination of serum propranolol or metoprolol levels were taken at the completion of the test. All tests were performed by the same investigator. Serum propranolol and metoprolol assay Serum propranolol and metoprolol concentrations were measured by high pressure liquid chromatography according to a modification of the method of Nygard.12 Statistical analysis Statistical analysis of changes in tremor amplitude was carried out using the Wilcoxon's test for paired differences. Analysis of changes in pulse rate was carried out by means of Student's t test for paired data. Parameters determined during each active treatment period were compared with those determined after an equivalent period of placebo. Results TREMOR FREQUENCY AND AMPLITUDE DURING PLACEBO The frequency of the dominant peak of hand tremor in the patients included in the study ranged from 4-2 to 10-0 Hz (median 7-2 Hz). In any individual patient the peak frequency of tremor varied somewhat on the two occasions of recording but when all patients were considered the difference was not statistically significant. The magnitude of hand tremor at the dominant frequency ranged from to g (median g), which in terms of actual hand displacement corresponds to an amplitude of mm (median mm). Two patients had placebo discontinued after a period of two weeks because tremor interfered seriously with their daily activities. On the other hand, four patients had during placebo treatment tremor amplitude below 0 02 mm, which is considered to be the upper limit of amplitude of physiological hand tremor in our laboratory (unpublished data). The same patients had consistently shown pathological values of tremor amplitude on several occasions before their recruitment in the study, an observation that underlines the marked placebo response in this type of disease. EFFECTS OF METOPROLOL AND PROPRANOLOL Tremor Only 13 patients received propranolol and metoprolol at the higher dosages (see below under Adverse Effects). Neither drug had any significant influence on the dominant peak frequency of tremor. At a dosage of 120 mg daily, propranolol was found to be superior to placebo on the basis of the performance tests (p < 0-05) and patient's selfassessment (p < 0 01). Propranolol 240 mg daily was superior to placebo on accelerometric assessment
3 Controlled study ofmetoprolol and propranolol during prolonged administration (p < 002), performance tests (p < 0-01), clinical assessment (p < 0 05) and patients' self-assessment (p < 0 01). The median reductions in tremor amplitude during propranolol treatment at the dosages of 120 and 240 mg were 25% (NS) and 45% (p < 0-02) respectively (comparison made with the placebo period). The reduction in tremor amplitude at the higher dosage did not differ from that observed at the lower dosage (fig 1). There was a trend for the amplitude of tremor to be lower during metoprolol treatment as compared to placebo (median reductions 13% at the 150 mg dosage and 32% at the 300 mg dosage), but the effect was not statistically significant. At neither of the two dosages used did the effect of metoprolol differ from that of placebo, irrespective of the method of assessment (figs 1 and 2). When the reductions in tremor amplitude (expressed as absolute or percent change values) produced by metoprolol and propranolol at dosages having equipotent f 1- blocking activity were compared, no statistically significant difference could be found between the two drugs. However, propranolol at a dosage of 120 mg daily was superior to metoprolol (150 mg daily) on the basis of clinical assessment (p < 0-05) and patient's self assessment (p < 0-01). At the dosage of 240 mg daily, propranolol was superior to metoprolol (300 mg daily) on the basis of patient's self-assessment (p < 0-05) (fig 2). Four patients on propranolol and three patients on metoprolol were found to have tremor amplitudes within the range of physiological tremor (< 0-02 mm hand displacement). When asked which of the three treatments they E * I.A 4t ;,\ p- n=16 n=13 ~ Fig 1 Effect ofpropranolol and metoprolol on tremor amplitude in the patients included in the study. i_ 3 (A v} o U0 _tn - : =.,o. Ir It A-.',''.'.' *AaI n= r e6' 895 n=12 Fig 2 Mean scorefor clinical assessment, performance tests and patient's self-assessment during propranolol, metoprolol and placebo treatments. Bars represent mean + sem (*p < 0 05 and tp < 0-01 as compared to placebo; Ap < 0 05 and t p < 0 01 as compared to metoprolol). considered best, six patients chose propranolol, two patients metoprolol and one patient placebo. Six patients could not find any difference between the three treatments, whereas one patient found propranolol as effective as placebo but superior to metoprolol. Pulse rate The tachycardic response on standing was lower during active drug treatments than during placebo (fig 3). The difference, however, was statistically significant only at the higher dosages of both metoprolol and propranolol. The degree of inhibition of standing tachycardia was similar for the two drugs. Serum propranolol and metoprolol levels Serum concentrations of propranolol were found to vary from 21-0 to ng/ml (median 44-0 ng/ml) and
4 896 C Fig n=16 n=12 ax Effect of the various treatments on standing tachycardia. Bars represent the mean sem (*p < 001 as compared to placebo). frm60 0 to ng/ml (median 1 13~ 1 ng/ml) on daily dosage of 120 mg and 240 mg respectively. Serum metoprolol levels ranged from less than 5 ng/ml to 19P 0 nglml (median 80-0 ng/ml) on the lower daily dosage and from less than 5 nglml to 555*6 ng/ml (median 206~8 ng/ml) on the higher daily dosage of the drug. Adverse effects Adverse effects were reported by an appreciable proportion of patients with the two active treatments and placebo. These effects are summarised in the table. Owing to the occurrence of breathlessness two patients received only the lower doses of both propranolol and metoprolol. A third patient, because of failure to attend the clinic, Table Side effects Number ofpatients Propranolol Metoprolol Placebo Tiredness Headache 2 - I Vivid dreams Loss of concentration Breathlessness Sedation, depression Blurred vision Feeling of unreality, sleeplessness Muscle pain on exercise Anxiety, irritability Sexual difficulty Calzetti, Findley, Perucca, Richens received only the lower dose of propranolol. In no case were side effects sufficiently severe to cause a patient's withdrawal from the study. Discussion The present study failed to provide a demonstration that metoprolol, at dosages as high as 300 mg daily, is effective in the treatment of essential tremor. Although there was a tendency for our patients to do better on metoprolol than on placebo, the difference failed to reach statistical significance, irrespective of dosage or method of assessment. In contrast, propranolol at the dosage of 120 mg daily was found to be superior to placebo on performance tests and patient's self assessment, whereas at the higher dosage (240 mg daily) it was superior to placebo on all the methods of assessment used. When dosages having equivalent J3 -blocking activity were compared, propranolol proved to be significantly better than metoprolol on the basis of clinical assessment and patient's self-evaluation. Our results are in agreement with those of Leigh et al who found metoprolol (50 mg twice daily) less effective than sotalol (80 mg twice daily) and no better than placebo in reducing the severity of essential tremor in 17 patients. On the other hand, our results are partly in contrast with those reported by Larsen and Teravainen8 who found metoprolol (50 mg three times daily) superior to placebo (even though less so than propranolol, 80 mg three times daily) in reducing tremor amplitude in 24 patients. The most interesting comparison can be made with the results of our previous study, in which single oral doses of metoprolol and propranolol9 were found to be better than placebo and virtually equipotent in the same population of patients. We cannot give any clear explanation for the apparent loss or reduction of efficacy of metoprolol during prolonged administration. It may be argued that it is usually more difficult to demonstrate a statistically significant drug effect when the evaluation of its pharmacodynamic action is made at long intervals of time and the symptom (essential tremor) is subject to considerable day-to-day variability. However, under the same experimental conditions and in the same patients it was possible to show a clearcut effect of propranolol at dosages that are considered to be equipotent in terms of f,-blockade. A second possible explanation for the discrepancies between the results of the acute and of the chronic study may be related to differences in protocol. While in the acute study metoprolol was given as a single 150 mg dose 90 minutes before tremor assessment, in the chronic study the drug was given in divided daily administrations so that the individual dose taken before the assessment was
5 Controlled study ofmetoprolol and propranolol during prolonged administration smaller (50 or 100 mg). Moreover, in the chronic study the interval between drug intake and time of assessment (usually min) could not be so rigidly standardised. Since metoprolol is rapidly absorbed, has a short half-life and does not accumulate during repeated administration, it is possible that the serum concentration of the drug at the time of tremor assessment was greater during the acute study. Since serum metoprolol concentrations in that study were not measured, this possibility cannot be excluded. In this regard, it is noteworthy that serum propranolol concentrations in the range of that obtained following a single oral dose (120 mg)'3 were achieved with 240 mg of the drug when administered chronically. However, since the pharmacokinetic differences between propranolol and metoprolol are not very marked, it is difficult to envisage how these could account for such a clear-cut differential response between these drugs in the two studies. Furthermore, the serum concentration of metoprolol (300 mg daily) at the time of assessment was sufficient to inhibit standing tachycardia to at least the same extent of that produced by the higher dosage of propranolol (fig 3). Another possibility that needs to be considered is that tolerance to the tremorolytic properties of the two fl-blockers developed. In the only controlled study' in which metoprolol was found to be effective, the drug was, however, given for no longer than one week. In our own patients, there was a tendency for the response to propranolol to be less marked after prolonged administration as compared to that observed following a single oral dose9 (at dosages producing similar serum drug concentrations). It is possible, however, that during chronic administration the effect of propranolol was mediated by some additional mode of action, not shared by metoprolol and to which tolerance did not develop. It has been suggested that f I-selective adrenoceptor blocking drugs are less valuable than nonselective drugs in the treatment of essential tremor, 14 but this view has been questioned. 5 Since the cardioselectivity of metoprolol is at least partially lost at doses higher than mg,'6 the more favourable long-term response to propranolol in our patients cannot be taken as sound evidence that the tremorolytic effect was related to blockade of 132- receptors. Whatever the explanation for the disappointing response to prolonged administration of metoprolol, our results strongly suggest that in the absence of specific contraindications propranolol should be preferred to metoprolol in the treatment of essential tremor. We would like to thank the physicians at the National Hospital, Queen Square, London, for allowing us to study patients under their care. We also thank the staff of the pharmacy at the National Hospital for their assistance. We are grateful to Dr J Ward, Dept of Clinical Pharmacology, Groby Road Hospital, Leicester, for measuring propranolol and metoprolol serum levels. SC has been supported by a European Science Foundation fellowship, European Training Programme in Brain and Behaviour Research (Strasbourg, France). References 897 Ljung 0. Treatment of essential tremor with metoprolol. N Eng J Med 1979;301: Britt CW. Peters BH. Metoprolol for essential tremor. N Engl J Med 1979;301:331. Riley T, Fleet AB. Metoprolol tartrate for essential tremor. N EngliJ Med 1979;301: Newman RP, Jacobs L. Metoprolol in essential tremor. Arch Neurol 1980;37: Turnbull DM, Shaw DA. Metoprolol in essential tremor. Lancet 1980;i:95. 6 Jefferson D, Jenner P, Marsden CD. 6l-adrenoceptor antagonists in essential tremor. J Neurol Neurosurg Psychiatry 1979;42: Leigh PN, Marsden CD, Twomey A, Jefferson D. 13-adrenoceptor antagonists and essential tremor. Lancet 1981 ;i: Larsen TA, Teravainen H.,6-blockers in essential tremor. Lancet 1981;ii:533. Calzetti S, Findley LJ, Gresty MA, Perucca E, Richens A. Metoprolol and propranolol in essential tremor: a double-blind controlled study. J Neurol Neurosurg Psychiatry 1981;44: '0 Johnsson G, Nyberg G. Solvell L. Influence of metoprolol and propranolol on hemodynamic effects induced by physical work and isoprenaline. Acta Pharmacol Toxicol (Kbh) 1975 ;36:69-75 (suppl V). Carruthers SG, Ghosal AG, McDevitt DG, Nelson JK, Shanks RG. The assessment of fl-adrenoceptor blocking drugs in hyperthyroidism. Br J Clin Pharmacol 1974;1: Nygard G, Shelver WM, Wahba Khalil SK. Sensitive high pressure liquid chromatographic determination of propranolol in plasma. J Pharm Sci 1979;68: Calzetti S, Findley U, Gresty MA, Perucca E, Richens A. The effect of an oral dose of propranolol on essential tremor. A double-blind controlled study. Am Neurol (in press). Beta-blockers in essential tremor (Editorial). Lancet 1979;ii: '5 Ljung 0. Metoprolol in essential tremor. Lancet 1980; i: Koch-Weser J. Metoprolol. N Engl J Med 1979; 301:
Metoprolol and propranolol in essential tremor: a double-blind, controlled study
Journal ofneurology, Neurosurgery, and Psychiatry 1981:44:814-819 Metoprolol and propranolol in essential tremor: a double-blind, controlled study S CALZETTI,* LJ FINDLEY,t MA GRESTY,t E PERUCCA,* A RICHENS*
More informationPrimidone in essential tremor of the hands and head:
Journal of Neurology, Neurosurgery, and Psychiatry 1985;48:911-915 Primidone in essential tremor of the hands and head: a double blind controlled clinical study LESLIE J FINDLEY,* LYNN CLEEVES,t STEPHANO
More informationAND PROPRANOLOL IN HYPERTHYROIDISM
Br. J. clin. Pharmac. (78),,-7 COMPARATIVE TRIAL OF ATENOLOL AND PROPRANOLOL IN HYPERTHYROIDISM D.G. McDEVITT Department of Therapeutics and Pharmacology, The Queen's University, Belfast, Northern Ireland
More informationFrequency/amplitude characteristics of postural tremor of the hands in a population of patients with
Journal of Neurology, Neurosurgery, and Psychiatry 1987;5:561-567 Frequency/amplitude characteristics of postural tremor of the hands in a population of patients with bilateral essential tremor: implications
More informationquantitative tremor recording
Journal of Neurology, Neurosurgery, and Psychiatry, 1981, 44, 677-683 Effects of timolol and atenolol on benign essential tremor: placebo-controlled studies based on quantitative tremor recording PER DIETRICHSON
More informationby severe excercise, an accepted method for In addition, practolol had a proportionately larger effect on exc6rcise tachycardia than it had on
Br. J. clin. Pharmac. (1975), 2, 411-416 COMPARATIVE TRIAL OF PROPRANOLOL AND PRACTOLOL IN J.K. NELSON The Ulster Hospital, Dundonald, Belfast, N. Ireland HYPERTHYROIDISM D.G. McDEVITT Department of Therapeutics
More informationDifferential effects of alpha-adrenoceptor blockade
Journal of Neurology, Neurosurgery, and Psychiatry 1985;48: 1031-1036 Differential effects of alpha-adrenoceptor blockade on essential, physiological and isoprenaline-induced tremor: evidence for a central
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More information(LONG ACTING FORMULATION) AND BENDROFLUAZIDE
Br. J. clin. Pharmac. (1982), 14, 727-732 COMPARATIVE PHARMACOLOGICAL AND PHARMACOKINETIC OBSERVATIONS ON PROPRANOLOL (LONG ACTING FORMULATION) AND BENDROFLUAZIDE ADMINISTERED SEPARATELY AND CONCURRENTLY
More informationEffects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris
Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments
More informationFelodipine vs hydralazine: a controlled trial as third line therapy
Br. J. clin. Pharmac. (1986), 21, 621-626 Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension CO-OPERATIVE STUDY GROUP* *Members of the co-operative study group were: Responsible
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationA double-blind comparison of bisoprolol and atenolol in patients with essential hypertension
QJ Med 995; 88:55-5 A double-blind comparison of bisoprolol and atenolol in patients with essential hypertension N.M. WHEELDON, T.M. MacDONALD, N. PRASAD, D. MACLEAN, L. PEEBLES and D.G. McDEVITT From
More informationeffects of intravenous labetalol
Pharmacological basis for antihypertensive effects of intravenous labetalol D. A. RICHARDS,' B. N. C. PRICHARD, A. J. BOAKES, J. TUCKMAN, AND E. J. KNIGHT2 From the Department of Clinical Pharmacology,
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Third generation beta-blockers in the treatment of arterial hypertension Kurt Stoschitzky, MD, FESC Division of Cardiology Department of Internal Medicine Medical University,
More informationAdrenergic hypersensitivity after beta-blocker
BHJ 460/80 Adrenergic hypersensitivity after beta-blocker withdrawal P J ROSS, M J LEWS, D J SHERDAN, A H HENDERSON Br Heart7 1981; 45: 637-42 From the Departments of ardiology and Pharmacology, Welsh
More informationIN THE TREATMENT OF HYPERTENSION
Br. J. clin. Pharmac. (1981), 12, 887-891 A MPARATIVE STUDY OF ATENOLOL AND METOPROLOL IN THE TREATMENT OF HYPERTENSION S. RASMUSSEN, K. ARNUNG, P.C. ESKILDSEN & P.E. NIELSEN Medical Department C, Diakonissestiftelsen,
More informationSalmeterol, a new long acting inhaled,f2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients
Thorax 1988;43:674-678 Salmeterol, a new long acting inhaled,f2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients ANDERS ULLMAN, NILS SVEDMYR From the Department of Clinical
More informationComparison of atenolol with propranolol in the treatment of angina pectoris with special reference to once daily administration of atenolol
British Heart Journal, 1978, 40, 998-1004 Comparison of atenolol with propranolol in the treatment of angina pectoris with special reference to once daily administration of atenolol GRAHAM JACKSON, JOHN
More informationPLASMA PROTEIN BINDING OF PROPRANOLOLAND ISOPRENALINE
Br. J. clin. Pharmac. (1978), 6, 123-127 PLASMA POTEIN BINDING OF POPANOLOLAND ISOPENALINE IN HYPETHYOIDISM AND HYPOTHYOIDISM J.G. KELLY & D.G. McDEVflT Department of Therapeutics and Pharmacology, The
More information100 mg atenolol equivalent to metoprolol
100 mg atenolol equivalent to metoprolol Metoprolol is a selective beta-blocker at dosages usually prescribed to lower blood. For High Blood Pressure For 7 years I have been on 50 mg. of atenolol for.
More informationpropranolol on essential tremor
Journal of Neurology, Neurosurgery, and Psychiatry, 1973, 36, 618-624 Effect of the beta adrenergic blocking agent propranolol on essential tremor M. HILARY MORGAN, R. LANGTON HEWER, AND RAY COOPER From
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A7772 September 25 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
More informationAntihypertensive efficacy of olmesartan compared with other antihypertensive drugs
(2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal
More informationPharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol
Br. J. clin. Pharmac. (1984), 17, 97S-12S Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol H. SPAHN', W. KIRCH2,. MUTSCHLR',.. OHNHAUS2, N. R. KITFRINGHAM2,
More informationEvidence Supporting Post-MI Use of
Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines? Michael B. Fowler, MB, FRCP Beta-adrenergic blocking
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationThe disposition of primidone in elderly patients
Br. J. clin. Pharmac. (1990), 30, 607-611 The disposition of primidone in elderly patients C. MARTINESl*, G. GATTIl, E. SASS02, S. CALZETIT2 & E. PERUCCA' 'Clinical Pharmacology Unit, Department of Internal
More informationBRIEF COMMUNICATIONS. KEY WORDS: Ambulatory blood pressure monitoring, placebo effect, antihypertensive drug trials.
AJH 1995; 8:311-315 BRIEF COMMUNICATIONS Lack of Placebo Effect on Ambulatory Blood Pressure Giuseppe Mancia, Stefano Omboni, Gianfranco Parati, Antonella Ravogli, Alessandra Villani, and Alberto Zanchetti
More informationShould beta blockers remain first-line drugs for hypertension?
1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationB-blockers. Effects not related to Beta-Blockade
B-blockers Effects not related to Beta-Blockade It has been suggested that some intrinsic sympathomimetic activity is desirable to prevent untoward effects such as asthma or excessive bradycardia. Pindolol
More informationcombination (97 ± 8 beats min-'; 65 ± 4 beats cardiac output may be balanced by the vasodilatation
Br J clin Pharmac 1994; 37: 45-51 An assessment of lacidipine and atenolol in mild to moderate hypertension D. LYONS, G. FOWLER, J. WEBSTER, S. T. HALL' & J. C. PETRIE Clinical Pharmacology Unit, Department
More informationDespite the widespread use of triptans ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability
... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability Randal L. Von Seggern, PharmD, BCPS Abstract Objective: This article summarizes preclinical and clinical data for
More informationSYNOPSIS. Publications No publications at the time of writing this report.
Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release
More informationAnticholinergic withdrawal and benzhexol treatment
Journal of Neurology, Neurosurgery, and Psychiatry, 1973, 36, 936-941 Anticholinergic withdrawal and benzhexol treatment in Parkion's disease P. M. HORROCKS, D. J. VICARY, J. E. REES, J. D. PARKES, AND
More informationnicotine on some types of human tremor
J. Neurol. Neurosurg. Psychiat., 1966, 29, 214 Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor JOHN MARSHALL AND HAROLD SCHNIEDEN' Barcroft, Peterson, and Schwab
More informationEfficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials
Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationMETOTRUST XL-25/50 Metoprolol Succinate Extended-Release Tablets
METOTRUST XL-25/50 Metoprolol Succinate Extended-Release Tablets COMPOSITION Each film-coated tablet of Metotrust XL-25 contains: Metoprolol Succinate USP 23.75 mg equivalent to Metoprolol Tartrate 25
More informationNew antiepileptic drugs
Chapter 29 New antiepileptic drugs J.W. SANDER UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont
More information914. Application of accelerometry in the research of human body balance
914. Application of accelerometry in the research of human body balance A. Kilikevičius 1, D. Malaiškaitė 2, P. Tamošauskas 3, V. Morkūnienė 4, D. Višinskienė 5, R. Kuktaitė 6 1 Vilnius Gediminas Technical
More informationSHORT AND LONG MEMORIES IN OCTOPUS AND THE INFLUENCE OF THE VERTICAL LOBE SYSTEM
J. Exp. Biol. (1970), 53. 385-393 385 With 4 text-figures fprinted in Great Britain SHORT AND LONG MEMORIES IN OCTOPUS AND THE INFLUENCE OF THE VERTICAL LOBE SYSTEM BY J. Z. YOUNG Department of Anatomy,
More informationTreatment of Intractable Hemicrania Continua by Occipital Nerve Stimulation
Treatment of Intractable Hemicrania Continua by Occipital Nerve Stimulation 1 Sarah Miller MBBS, MRCP 2 Laurence Watkins FRCS, PhD and 1 Manjit Matharu FRCP, PhD 1 Headache Group, Institute of Neurology
More informationReversal by phenytoin of carbamazepine-induced
Journal of Neurology, Neurosurgery, and Psychiatry, 1980, 43, 540-545 Reversal by phenytoin of carbamazepine-induced water intoxication: a pharmacokinetic interaction E PERUCCA AND A RICHENS From the Clinical
More informationtolerance and subjective fatigue after metoprolol and atenolol in
Br. J. clin. Pharmac. (1991), 31, 391-398 ADONIS 3652519176 C Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects
More informationAIRNERGY REPORT. May Dr Nyjon Eccles BSc MBBS PhD MRCP The Chiron Clinic, Harley St, London, England W1G 6AX Tel:
AIRNERGY REPORT May 2004 Dr Nyjon Eccles BSc MBBS PhD MRCP The Chiron Clinic, Harley St, London, England W1G 6AX Tel: 0207 2244622 Abstract Six volunteers were recruited for a study of the effect of 4
More informationThe benefit of treatment with -blockers in heart failure is
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Philippe Lechat, MD, PhD; Jean-Sébastien Hulot, MD; Sylvie Escolano, MD, PhD; Alain Mallet,
More informationSalapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.
Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationExercise Training for PoTS and Syncope
B 140 120 100 80 60 40 20 0 Blood Pressure (mm Hg) Blood Pressure Heart Rate 60 degree Head Up Tilt Time 140 120 100 80 60 40 20 0 Heart Rate (beats.min -1 ) Exercise Training for PoTS and Syncope C Blood
More informationComposition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate).
VENTOL Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate). Respiratory Solution Action Salbutamol is a short-acting, relatively selective beta2-adrenoceptor agonist.
More informationVerapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design
Br J Clin Pharmacol 1998; 45: 491 495 Verapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design Juergen Scholze, 1 Peter Zilles 2 & Daniele Compagnone 2 on
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Study Endpoints: Pharmacokinetics:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationImprovement in angina pectoris with alpha adrenoceptor blockade
Br Heart J 1985; 53: 488-92 Improvement in angina pectoris with alpha adrenoceptor blockade PETER COLLINS, DESMOND SHERIDAN From die Departm of Cardiology, Welsh National School ofmedicine, Cardiff SUMMARY
More informationAdrenergic Receptor as part of ANS
Adrenergic Receptor as part of ANS Actions of Adrenoceptors Beta-1 adrenergic receptor Located on the myocytes of the heart Specific actions of the β1 receptor include: 0 Increase cardiac output, by 0
More informationA trial of opipramol in the treatment of migraine
Journal of Neurology, Neurosurgery, and Psychiatry, 1972, 35, 500-504 A trial of opipramol in the treatment of migraine HARRY JACOBS From Severalls Hospital, Colchester SUMMARY A double blind trial of
More informationIndividual Study Table Referring to Part of the Dossier. Volume:
Final Report M/100977/21Final Version () 2. SYNOPSIS A Title of Study: A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationA Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl Citrate
Vol. 26 No. 2 August 2003 Journal of Pain and Symptom Management 743 Original Article A Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl
More informationMetoprolol -a new cardioselective 3-adrenoceptor blocking agent for treatment of tachyarrhythmias
British Heart journal, 1977, 39, 834-838 Metoprolol -a new cardioselective 3-adrenoceptor blocking agent for treatment of tachyarrhythmias H. S. WASIR, R. K. MAHAPATRA, M. L. BHATIA, SUJOY B. ROY, AND
More informationAbuse Potential of Morphine/ Dextromethorphan Combinations
S26 Journal of Pain and Symptom Management Vol. 19 No. 1(Suppl.) January 2000 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia Abuse Potential of Morphine/ Dextromethorphan
More informationCLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS
CLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS Guideline Title Clinical Investigation of Anti-Anginal Medicinal Products in Stable Angina Pectoris Legislative basis
More informationPractolol and bendrofluazide in treatment of hypertension
British Heart Journal, I974, 36, 867-87I. Practolol and bendrofluazide in treatment of hypertension D. B. Galloway, A. G. Beattie, and J. C. Petrie From Department of Therapeutics and Clinical Pharmacology,
More informationEffect of brimonidine on intraocular pressure in normal tension glaucoma: A short term clinical trial
European Journal of Ophthalmology / Vol. 13 no. 7, 2003 / pp. 611-615 Effect of brimonidine on intraocular pressure in normal tension glaucoma: A short term clinical trial S.A. GANDOLFI, L. CIMINO, P.
More informationa 1 -adrenoceptor antagonist on uro owmetric parameters in patients with benign prostatic hyperplasia
Single dose methodology to assess the in uence of an a 1 -adrenoceptor antagonist on uro owmetric parameters in patients with benign prostatic hyperplasia S. P. Curtis, 1 I. Eardley, 2 M. Boyce, 3 P. Larson,
More informationBETAGAN Allergan Levobunolol HCl Glaucoma Therapy
BETAGAN Allergan Levobunolol HCl Glaucoma Therapy Action And Clinical Pharmacology: Levobunolol is a noncardioselective beta- adrenoceptor antagonist, equipotent at both beta1 and beta2 receptors. Levobunolol
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationTHE ACUTE AND CHRONIC BRONCHODILATOR
Br. J. clin. Pharmac. (1975), 2, 533-537 THE ACUTE AND CHRONIC BRONCHODILATOR EFFECTS OF EPHEDRINE IN ASTHMATIC PATIENTS C.S. MAY, M.E. PICKUP & J.W. PATERSON Asthma Research Council Clinical Pharmacology
More informationDRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU
Original Article DRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU V.Gowri 1, K.Punnagai, K.Vijaybabu 3, Dr.Darling Chellathai 4 1 Assistant Professor
More informationWhen choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.
... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends
More informationMorphiDex (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S37 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia MorphiDex (MS:DM) Double-Blind, Multiple-Dose
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
Anand IS,, 2014; Volume 3(3): 178-187 INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE EFFECT OF NEBIVOLOL AND METOPROLOL ON PLATELET ACTIVATION IN HYPERTENSIVE PATIENTS ANAND IS, PATEL
More informationNon Thyroid Surgery. In patients with Thyroid disorders
Non Thyroid Surgery In patients with Thyroid disorders The Thyroid disease problem. Is Thyroid disease a problem with anaesthetic? Why worry? The Physiology The evidence. A pragmatic approach From: The
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationLESSON ASSIGNMENT Given the trade and/or generic name of an adrenergic blocking agent, classify that agent as either an alpha or beta blocker.
LESSON ASSIGNMENT LESSON 8 Adrenergic Blocking Agents. TEXT ASSIGNMENT Paragraphs 8-1 through 8-5. LESSON OBJECTIVES 8-1. Given a group of statements, select the statement that best describes one of the
More informationPhenytoin and postoperative epilepsy
J Neurosurg 58:672-677, 1983 Phenytoin and postoperative epilepsy A double-blind study J. BRIAN NORTIt, F.R.A.C.S., ROBERT K. PENHALL, F.R.A.C.P., AttMAD HANIEH, F.R.A.C.S., DEREK B. FREWIN, F.R.A.C.P.,
More informationTreatment of Influenza. Dr. YU Wai Cho
Treatment of Influenza Dr. YU Wai Cho Symptomatic Treatment Analgesics/ Antipyretics (avoid aspirin) Adequate fluids Rest Specific Drug Treatment Synthetic amines Amantadine Rimantadine Neuraminidase inhibitors
More informationTHE ROLE OF ADRENERGIC MECHANISM IN TREMORINE INDUCED TREMORS IN RATS: ANTITREMOR EFFECT OF
THE ROLE OF ADRENERGIC MECHANISM IN TREMORINE INDUCED TREMORS IN RATS: ANTITREMOR EFFECT OF ~-ADRENOCEPTOR ANTAGONISTS VANAJA PAUL* Department of Pharmacology, Christian Medical College, Ludhiana - 141
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 CARDENSIEL 1.25 mg, film-coated tablet B/30 (CIP code: 352 968-1) CARDENSIEL 2.5 mg, film-coated tablet
More informationSYNOPSIS. Co-ordinating investigator Not applicable. Study centre(s) This study was conducted in Japan (57 centres).
Drug product: Symbicort Turbuhaler Drug substance(s): ST (Symbicort Turbuhaler ) Edition No.: 1.0 Study code: D5890C00010 Date: 15 March 2007 SYNOPSIS An 8-week, randomised, double blind, parallel-group,
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION MIRABEGRON (Myrbetriq Astellas Pharma Canada Inc.) Indication: Overactive Bladder Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that mirabegron be listed
More informationStudy No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods: Sample Size
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTable 1. Relevant Publications by Company Investigators and Colleagues
Table 1. Relevant Publications by Company Investigators and Colleagues Study Objective Results Conclusions To determine Mean peak count frequency before whether OMT can administration of propofol determine
More informationQuantitative Assessment of Botulinum Toxin Treatment in 43 Patients with Head Tremor
~~~~~ ~ ~ Movement Disorder& Vol. 12, NO. 5, 1997, pp 122-126 0 1997 Movemcnt Disorder Society Quantitative Assessment of Botulinum Toxin Treatment in 43 Patients with Head Tremor "tjorg Wissel, "Florian
More informationMr. Eknath Kole M.S. Pharm (NIPER Mohali)
M.S. Pharm (NIPER Mohali) Drug Class Actions Therapeutic Uses Pharmacokinetics Adverse Effects Other Quinidine IA -Binds to open and inactivated Na+ -Decreases the slope of Phase 4 spontaneous depolarization
More informationAssessing tremor severnty
8688ournal ofneurology, Neurosurgery, and Psychiatry 1993;56:868-873 MRC Human Movement and Balance Unit, The Institute of Neurology, Queen Square, London WCIN 3BG, UK P G Bain L J Findley P Atchison M
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationThere is convincing evidence in clinical studies
AJH 1998;11:1413 1417 Reliability of Reporting Self-Measured Blood Pressure Values by Hypertensive Patients Thomas Mengden, Rosa Maria Hernandez Medina, Belen Beltran, Elena Alvarez, Karin Kraft, and Hans
More informationGastric, intestinal and colonic absorption of metoprolol in
Br. J. clin. Pharmac. (1985), 19, 85S-89S Gastric, intestinal and colonic absorption of metoprolol in the rat J. DOMENECH', M. ALBA', J. M. MORERA', R. OBACH' & J. M. PLA DELFINA2 'Department of Pharmaceutics,
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationNew Medicines Profile
New Medicines Profile February 2010 Issue No. 10/02 Eslicarbazepine Concise evaluated information to support the managed entry of new medicines in the NHS Brand Name, (Manufacturer): Zebinix (Eisai Limited)
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More information: /18
612.461.23: 616-001.17/18 SOME OBSERVATIONS ON THE COMPARATIVE EFFECTS OF COLD AND BURNS ON PROTEIN METABOLISM IN RATS. By G. H. LATHE 1 and R. A. PETERS. From the Department of Biochemistry, Oxford. (Received
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
2 CLINICAL STUDY SYNOPSIS FINAL REPORT N0. CCD-0402-RS-0002 Title of the study: Evaluation of the 24-hour trough FEV 1 following 7 days of dosing with 2 µg once daily. A multicentre, double-blind, double-dummy,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationScottish Medicines Consortium
Scottish Medicines Consortium valsartan 40mg, 80mg and 160mg capsules and tablets (Diovan ) No. (162/05) Novartis Pharmaceuticals New Indication: following myocardial infarction in patients with clinical
More information